Bio News

Orum Therapeutics raised 145 billion won in follow-on funding in January this year to advance development of next-generation antibody-drug conjugates (DACs). The funds will be used for preclinical research on follow-on pipelines for the TPD² platform based on GSPT1 degraders. The lead pipeline, ORM-6151, which was licensed to BMS for 234 billion won, is currently in a phase 1 clinical trial.

BIOBOOK TEAM
biobookmedia@biobook.co.krDaewoong Pharmaceutical’s Flodicitinib Achieves More Than 90% Target Occupancy in Phase 1 Trial
Aribio’s AR1001 Meets Primary Endpoint in Phase 3 Alzheimer’s Trial
GC녹십자 Signs MOU With Dongbang FTL to Collaborate on LNP Production
CG Oncology: Cretostimogene Cuts Bladder Cancer Recurrence Risk by 68%; FDA Filing to Expand
CG Oncology: 68% Lower Risk of Bladder Cancer Recurrence; Shares Surge 12%
U.S. FDA Rejects Summit and Akeso’s PD-1/VEGF Lung Cancer Drug